These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3835175)

  • 1. Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: impact of tumour site, patient age and magnesium suppletion.
    Blom JH; Kurth KH; Splinter TA
    Int Urol Nephrol; 1985; 17(4):331-9. PubMed ID: 3835175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man.
    Mavichak V; Coppin CM; Wong NL; Dirks JH; Walker V; Sutton RA
    Clin Sci (Lond); 1988 Aug; 75(2):203-7. PubMed ID: 3409636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cis-platinum: a new anticancer agent.
    Williams CJ; Whitehouse JM
    Br Med J; 1979 Jun; 1(6179):1689-91. PubMed ID: 380759
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the serum, liver, and renal cortical lipids and electrolytes in rabbits with cisplatin-induced nephrotoxicity.
    Abdel-Gayoum AA; Ahmida MHS
    Turk J Med Sci; 2017 Jun; 47(3):1019-1027. PubMed ID: 28618760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hypomagnesemia caused by cisplatin: effect of calcitriol.
    Sutton RA; Walker VR; Halabe A; Swenerton K; Coppin CM
    J Lab Clin Med; 1991 Jan; 117(1):40-3. PubMed ID: 1987306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
    Markman M; Cleary S; Howell SB
    Am J Clin Oncol; 1986 Oct; 9(5):440-3. PubMed ID: 3776908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
    Vogelzang NJ; Torkelson JL; Kennedy BJ
    Cancer; 1985 Dec; 56(12):2765-70. PubMed ID: 2413982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
    Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
    Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of concurrent cisplatin and radiation therapy in locally advanced bladder cancer.
    Utsunomiya M; Itoh H; Yoshioka T; Masaki N; Itatani H
    Br J Urol; 1992 Oct; 70(4):399-403. PubMed ID: 1450848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.
    Lee YK; Shin DM
    Korean J Intern Med; 1992 Jul; 7(2):118-21. PubMed ID: 1339077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persisting renotubular sequelae after cisplatin in children and adolescents.
    Bianchetti MG; Kanaka C; Ridolfi-Lüthy A; Hirt A; Wagner HP; Oetliker OH
    Am J Nephrol; 1991; 11(2):127-30. PubMed ID: 1951473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium supplementation and ototoxicity in patients receiving cisplatin.
    Grau JJ; Estapé J; Cuchi MA; Fírvida JL; Blanch JL; Ascaso C
    Br J Clin Pharmacol; 1996 Aug; 42(2):233-5. PubMed ID: 8864323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
    Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cisplatin].
    Ogawa M
    Gan To Kagaku Ryoho; 1984 May; 11(5):1140-6. PubMed ID: 6326687
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
    Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced bladder cancer using cis-platinum.
    Harewood LM; Nunn I; Johnson W; Sullivan JR; Moon WJ; Leyden MJ
    Aust N Z J Surg; 1983 Aug; 53(4):333-7. PubMed ID: 6193775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of nephrotoxicity by hydration-diuresis, and of emesis by alizapride, during cisplatin administration in patients with bladder cancer.
    Neri B; Bartalucci S; Rizzo P; Nicita G; Ponchietti R
    Riv Eur Sci Med Farmacol; 1988 Nov; 10(5):389-92. PubMed ID: 3079128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.